Glucocorticoid-Induced Skin Atrophy: The Old and the New

Area of Science:

• Dermatology
• Pharmacology
• Cell Biology

Background:

• Topical glucocorticoids are widely used for inflammatory skin conditions due to their anti-inflammatory, vasoconstrictive, immune suppressive, and antiproliferative properties.
• Despite their therapeutic benefits, topical glucocorticoids are associated with significant adverse effects, including skin atrophy, striae, rubeosis, and acne.

Purpose of the Study:

• To review the beneficial and adverse effects of topical glucocorticoids in dermatology.
• To highlight the mechanisms underlying skin atrophy induced by topical glucocorticoids.
• To emphasize the need for cautious prescription and development of novel therapies.

Main Methods:

• Literature review of studies on topical glucocorticoid efficacy and side effects.
• Analysis of the impact of topical glucocorticoids on epidermal and dermal structures.
• Examination of atrophogenic changes in skin appendages.

Main Results:

• Topical glucocorticoids alter epidermal structure and stratum corneum components, impairing skin barrier integrity.
• Dermal changes include inhibited fibroblast proliferation, reduced mast cells, collagen synthesis inhibition, and depletion of essential matrix components.
• Skin atrophy manifests as hypoplasia, elasticity loss, increased fragility, telangiectasia, and impaired barrier function.

Conclusions:

• Topical glucocorticoids, while effective for inflammatory dermatoses, pose a risk of significant skin atrophy and barrier dysfunction.
• Understanding the mechanisms of atrophogenic effects is vital for managing treatment risks.
• Future research should focus on developing safer, targeted therapies to optimize the benefit-risk ratio.